We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: atrial fibrillation
MedXY News
EnglishTag

atrial fibrillation

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Catheter Ablation and Edoxaban for Secondary Stroke Prevention: Critical Analysis of the STABLED Randomized Trial
Cardiologyatrial fibrillationcatheter ablation

Catheter Ablation and Edoxaban for Secondary Stroke Prevention: Critical Analysis of the STABLED Randomized Trial

By MedXY|Mar 2, 2026

The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a

Integrating Serum Metabolomics and Polygenic Risk Scores Redefines 5-Year Atrial Fibrillation Prediction
Cardiologyatrial fibrillationmetabolomics

Integrating Serum Metabolomics and Polygenic Risk Scores Redefines 5-Year Atrial Fibrillation Prediction

By MedXY|Mar 2, 2026

A massive UK Biobank study demonstrates that combining serum metabolomics with polygenic risk scores and clinical data significantly improves the prediction of incident atrial fibrillation, identifying key metabolic markers like linoleic ac

NOACs Superior to Warfarin for Systemic Embolic Events: Lessons from a 71,683-Patient Meta-Analysis
Cardiologyatrial fibrillationCardiology

NOACs Superior to Warfarin for Systemic Embolic Events: Lessons from a 71,683-Patient Meta-Analysis

By MedXY|Mar 2, 2026

A large-scale individual patient data meta-analysis reveals that while systemic embolic events are less common than strokes in atrial fibrillation, they carry an equivalent mortality risk. NOACs significantly reduce this risk by 29% compare

Nurse-Led Integrated Care Slashes Recurrence and Boosts Quality of Life After Atrial Fibrillation Ablation
Cardiologyatrial fibrillationcatheter ablation

Nurse-Led Integrated Care Slashes Recurrence and Boosts Quality of Life After Atrial Fibrillation Ablation

By MedXY|Mar 2, 2026

The NURSECAT-AF trial demonstrates that structured nurse-led care significantly improves quality of life and reduces arrhythmia recurrence and emergency visits by 80% in patients undergoing their first catheter ablation for atrial fibrillat

Caffeinated Coffee Linked to 39% Lower Risk of Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial
Cardiologyarrhythmiaatrial fibrillation

Caffeinated Coffee Linked to 39% Lower Risk of Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

By MedXY|Feb 9, 2026

The DECAF randomized trial challenges the traditional view of caffeine as a trigger for atrial fibrillation, demonstrating that coffee consumption significantly reduces arrhythmia recurrence after cardioversion compared to total abstinence.

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
CardiologyAbelacimabatrial fibrillation

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

By MedXY|Feb 5, 2026

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients
Cardiologyatrial fibrillationcatheter ablation

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY|Feb 4, 2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
Cardiologyatrial fibrillationcatheter ablation

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY|Feb 4, 2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a

Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial
Cardiologyatrial fibrillation

Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial

By MedXY|Jan 22, 2026

The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, of

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial
Cardiologyatrial fibrillationcognitive decline

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

By MedXY|Jan 22, 2026

The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study
Cardiologyatrial fibrillationpolygenic risk score

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study

By MedXY|Jan 22, 2026

A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potent

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes
Cardiologyatrial fibrillationbiomarkers

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

By MedXY|Jan 22, 2026

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFp

Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden
Cardiologyatrial fibrillationcatheter ablation

Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden

By MedXY|Jan 21, 2026

A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidit

Predicting Stroke Recurrence: MRI Markers Outperform Location in Risk-Stratifying Patients with ICH and Atrial Fibrillation
Cardiologyatrial fibrillationNeuroimaging

Predicting Stroke Recurrence: MRI Markers Outperform Location in Risk-Stratifying Patients with ICH and Atrial Fibrillation

By MedXY|Jan 21, 2026

A secondary analysis of the PRESTIGE-AF trial reveals that specific MRI markers, including cortical superficial siderosis and macrohemorrhages, are more potent predictors of recurrent intracerebral hemorrhage than hematoma location alone, o

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
Cardiologyatrial fibrillationbiomarkers

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

By MedXY|Jan 18, 2026

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting

Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial
Cardiologyatrial fibrillationcardiomyopathy

Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial

By MedXY|Jan 17, 2026

The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in

Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF
Cardiologyatrial fibrillationclinical guidelines

Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF

By MedXY|Jan 17, 2026

The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention whe

Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management
Cardiologyanticoagulationatrial fibrillation

Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

By MedXY|Jan 7, 2026

A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s

Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes
Cardiologyatrial fibrillationCardiovascular Risks

Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes

By MedXY|Jan 6, 2026

A sub-analysis of the Harmony Outcomes trial demonstrates that albiglutide consistently reduces major adverse cardiovascular events in Type 2 diabetes patients, irrespective of baseline atrial fibrillation, while showing a trend toward redu

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy
CardiologyAlzheimer's diseaseanticoagulation

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy

By MedXY|Jan 6, 2026

A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h

Prev
3 / 6
123456
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities